Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ: CRVS · IEX Real-Time Price · USD
0.820
-0.005 (-0.62%)
At close: Feb 7, 2023, 3:59 PM
0.811
-0.009 (-1.09%)
After-hours: Feb 7, 2023, 5:54 PM EST
-0.62%
Market Cap 38.17M
Revenue (ttm) n/a
Net Income (ttm) -40.73M
Shares Out 46.55M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 121,829
Open 0.820
Previous Close 0.825
Day's Range 0.810 - 0.866
52-Week Range 0.695 - 2.170
Beta 1.01
Analysts Buy
Price Target 2.89 (+252.48%)
Earnings Date Mar 9, 2023

About CRVS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 23, 2016
Employees 28
Stock Exchange NASDAQ
Ticker Symbol CRVS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CRVS stock is "Buy." The 12-month stock price forecast is $2.89, which is an increase of 252.48% from the latest price.

Price Target
$2.89
(252.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Results in patients with refractory T cell lymphoma demonstrated CPI-818's anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoi...

2 months ago - GlobeNewsWire

Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PT Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at ...

2 months ago - GlobeNewsWire

James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology

BURLINGAME, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- James T. Rosenbaum, MD, Senior Vice President of Research at Corvus Pharmaceuticals (Nasdaq: CRVS), was presented with the Distinguished Service A...

3 months ago - GlobeNewsWire

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

Data From CPI-818 T Cell Lymphoma Study Accepted for Presentation at the 64th ASH Annual Meeting and Exposition; Advancing CPI-818 Development for Autoimmune and Allergic Diseases

3 months ago - GlobeNewsWire

Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT

3 months ago - GlobeNewsWire

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

3 months ago - GlobeNewsWire

Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

BURLINGAME, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of...

3 months ago - GlobeNewsWire

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China

Mupadolimab clinical trial in China will be conducted by Angel Pharmaceuticals Mupadolimab clinical trial in China will be conducted by Angel Pharmaceuticals

4 months ago - GlobeNewsWire

Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BURLINGAME, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will pre...

5 months ago - GlobeNewsWire

Corvus (CRVS) Moves to Buy: Rationale Behind the Upgrade

Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6 months ago - Zacks Investment Research

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Prioritizing Development of CPI-818 for T Cell Lymphomas, Autoimmune and Allergic Diseases

6 months ago - GlobeNewsWire

Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment o...

7 months ago - GlobeNewsWire

Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas

9 months ago - GlobeNewsWire

Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York

Company to host a webcast at 9:00am ET / 6:00am PT Company to host a webcast at 9:00am ET / 6:00am PT

10 months ago - GlobeNewsWire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT

11 months ago - GlobeNewsWire

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

1 year ago - GlobeNewsWire

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner ...

1 year ago - GlobeNewsWire

New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation

Data Presented in Poster Presentation at American Society of Hematology Annual Meeting Data Presented in Poster Presentation at American Society of Hematology Annual Meeting

1 year ago - GlobeNewsWire

Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Results in patients with relapsed refractory NSCLC and head and neck cancer demonstrate tumor reduction in patients treated with mupadolimab mono and combination therapy

1 year ago - GlobeNewsWire

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

BURLINGAME, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial r...

1 year ago - GlobeNewsWire

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals

1 year ago - GlobeNewsWire

Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818

JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd.

1 year ago - PRNewsWire

4 Buy-Ranked Stocks that Soared Over 20% in the Past Week

The market remains on its toes as investors digest the ton of information hitting us about now.

Other symbols: CVLGHRI
1 year ago - Zacks Investment Research

Corvus Posts Data From Discontinued Mupadolimab COVID-19 Program

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) has shared data from the Phase 3 mupadolimab COVID-19 trial. The data from 40 patients suggested improvement in the primary and key secondary endpoints in pat...

1 year ago - Benzinga

Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease

Announces results published online in medRxiv in 40 patients from COVID-19 randomized controlled study, which showed primary and secondary endpoints trend toward more favorable outcome for mupadolimab...

1 year ago - GlobeNewsWire